POLG

DNA polymerase subunit gamma-1 · P54098 · POLG on Sugi Atlas →

9,182 patent compounds predicted against POLG, 4,815 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Emtricitabine 5'-Triphosphate (SCHEMBL606449)	1.00	3/20
Lamivudine Triphosphate (SCHEMBL2223243)	1.00	3/20
SCHEMBL1274297	0.72	3/20
Ddctp (SCHEMBL210922)	0.70	3/20
SCHEMBL339369	0.68	3/20
Lamivudine (SCHEMBL377217)	0.67	3/20
SCHEMBL543438	0.67	3/20
SCHEMBL1333569	0.67	3/20
Lamivudine (SCHEMBL3198505)	0.67	3/20
Lamivudine (SCHEMBL3472481)	0.67	3/20
SCHEMBL3678709	0.67	3/20
SCHEMBL598860	0.66	3/20
SCHEMBL599699	0.66	3/20
SCHEMBL599700	0.66	3/20
Lamivudine (SCHEMBL33979)	0.62	3/20
Lamivudine (SCHEMBL109675)	0.62	3/20
Lamivudine (SCHEMBL465678)	0.62	3/20
Lamivudine (SCHEMBL2240686)	0.62	3/20
Lamivudine (SCHEMBL2305925)	0.62	3/20
Lamivudine (SCHEMBL2422788)	0.62	3/20

Clinical trials — most relevant to POLG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
PREventing Progression of Adipose Tissue Redistribution	PHASE4	COMPLETED
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	PHASE3	UNKNOWN
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	COMPLETED
Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment	PHASE2	ACTIVE_NOT_RECRUITING
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability	PHASE2	ACTIVE_NOT_RECRUITING
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers	PHASE1/PHASE2	COMPLETED
Olaparib in People With Malignant Mesothelioma	PHASE2	COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy	PHASE2	COMPLETED
Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer	PHASE2	COMPLETED
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN
Identification of Large-Scale Mutations of POLG Gene by QMPSF in Patients With Mitochondrial DNA Instability.	nan	UNKNOWN
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
Cohort of Tumors With POLE/D1 Mutation	nan	RECRUITING
Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility	nan	RECRUITING
Comparison of Oxidants and Antioxidants in Breastmilk Under Different Anesthesia Protocols	nan	COMPLETED
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification	nan	RECRUITING
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Prevalence of Germline Alterations in Actionable Genes in Endometrial Cancer	nan	NOT_YET_RECRUITING
Clinical Study of Hydroxytyrosol (HT) in Mitochondrial Diseases	nan	COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a POLG binder may also engage these)

Protein	Name	Similarity
Q9QYV8	—	1.000	Q9QYV8 →
P54099	—	0.998	P54099 →
Q91684	—	0.980	Q91684 →
Q8C0R7	—	0.977	Q8C0R7 →
PINK1	Serine/threonine-protein kinase PINK1, mitochondrial	0.976	landscape →
F1MLB4	—	0.974	F1MLB4 →
Q92076	—	0.974	Q92076 →
Q95K25	—	0.973	Q95K25 →
Q99MQ3	—	0.973	Q99MQ3 →
Q8BKF1	—	0.973	Q8BKF1 →
Q9D2Q2	—	0.973	Q9D2Q2 →
Q8N9W5	—	0.972	Q8N9W5 →
ABHD16A	Phosphatidylserine lipase ABHD16A	0.972	landscape →
Q4V7A9	—	0.971	Q4V7A9 →
Q4KLN4	—	0.971	Q4KLN4 →
Q8CC12	—	0.970	Q8CC12 →
Q8WVT3	—	0.970	Q8WVT3 →
Q8C3F2	—	0.970	Q8C3F2 →
Q3U5Q7	—	0.970	Q3U5Q7 →
A6QNT4	—	0.970	A6QNT4 →
Q0QWG9	—	0.969	Q0QWG9 →
POLRMT	DNA-directed RNA polymerase, mitochondrial	0.969	landscape →
Q5T7W7	—	0.969	Q5T7W7 →
Q8C2E4	—	0.969	Q8C2E4 →
F1ND48	—	0.969	F1ND48 →
B5DFG1	—	0.969	B5DFG1 →
Q1JPD2	—	0.969	Q1JPD2 →
MAP4K2	Mitogen-activated protein kinase kinase kinase kinase 2	0.969	landscape →
Q3UYV8	—	0.969	Q3UYV8 →
Q5TM59	—	0.969	Q5TM59 →